AZNCF News and Press, AstraZeneca Plc From 03/24/22

OKYO Pharma is a UK based developer of next generation ocular therapeutics based on GPCR and MRGPR. The company plans direct Phase 2 trial of its lead candidate following a pre-IND meeting with FDA. The company has filed F-1 for an IPO of its ADSs. For further details see: ...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

20 Dividend payments increased income 22.2% over Feb 2021 and raised forward income by 19.5%. Portfolio value is up 1.9% ytd, up 19.9% from Feb 2021, 23.2% from Jan 2021 and up 0.14% from last month. Complete listing of all 89 RIG companies and when they make their dividend paymen...

100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...

No matter how long is the time you dedicate to look at/hold AbbVie, it's a "movie" with a happy ending, with a second-to-none acting performance. In spite of near-future growth concerns, and even if the stock might be (technically/optically) looking fully valued, we believe that there...

The following slide deck was published by AstraZeneca PLC in conjunction with their 2021 Q4 earnings call. For further details see: AstraZeneca PLC 2021 Q4 - Results - Earnings Call Presentation

AstraZeneca PLC (AZN) Q4 2021 Earning Conference Call February 10, 2022 6:45 AM ET Company Participants Chris Sheldon - Head of Investor Relations Pascal Soriot - CEO & Executive Director Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncolog...

Since the acquisition of Alexion was completed, we were watching AstraZeneca from the sidelines. Holding but not taking any further action. Q4/FY 2021 earnings are marking a turning point for the company, for its future, for its dividend, and (consequently) for us. This has been nothi...

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Fisher’s 13F portfolio value increased from ~$161B to ~$179B in Q4 2021. Amazon, Netflix, Meta Platforms, and PayPal Holdings were increased while reducing Visa, Cisco Systems, Walt Disney, Intel, Wal-Mart, UnitedHealth, and Starbucks this quarter. The top three positions a...